Exosomes are small extracellular vesicles, approximately 40-150 nanometers in diameter, secreted by almost all types of cells and found in various bodily fluids such as blood, urine, saliva, and cerebrospinal fluid (CSF). They play a crucial role in intercellular communication by carrying and transferring molecules like proteins, lipids, and a variety of nucleic acid components to recipient cells. Exosomes are involved in a range of both physiological and pathological processes, including cell growth and migration, immune regulation, central nervous system (CNS) communication, stem cell maintenance, tissue repair, neurodegeneration, and cancer. Due to their natural biocompatibility and ability to carry therapeutic payloads, exosomes have gained considerable attention as potential drug delivery systems, disease biomarkers, and new therapeutic targets.
To advance life science research and drug discovery, AcceGen offers a comprehensive suite of exosome-related products. These products currently include exosomes derived from different species such as human, mouse and rat. They are generated from various sources including biofluid (plasma, serum, urine, saliva, CSF, breast milk, ascites) and different cell types such as stem cells (especialy mesenchymal stem cells), cancer cells, and primary cells, enabling scientists to study intercellular signaling, discover disease biomarkers, develop drug delivery systems and explore novel therapeutic targets.
| Mesenchymal Stem Cell-Derived Exosomes | Cancer Cell Line-Derived Exosomes | Primary Cell-Derived Exosomes |
 |
 |
 |
| Biofluid-Derived Exosomes | Others | |
 |
 |
The role of mesenchymal stem cell (MSC)-derived exosomes is gaining increasing attention in facilitating cell-to-cell communication, and playing a crucial role in tissue regeneration, inflammation modulation, immune regulation, and drug delivery. They are considered as a promising cell-free therapy for various diseases.
MSC-derived exosomes are less likely to induce tumorigenicity or immune rejection compared to MSCs themselves, and are easier to be produced and preserved than stem cells. Moreover, these exosomes can be engineered to target specific cells or tissues, enhancing their therapeutic efficacy. Overall, MSC-derived exosomes are a promising cell-free therapy with a wide range of potential applications in regenerative medicine and beyond.
AcceGen provides high-quality Human MSC-Derived Exosomes, supporting studies on the therapeutic applications of MSC-derived exosomes in wound healing, cardiovascular disease, Neurodegenerative disease, cancer, and other diseases such as osteoarthritis, graft-versus-host disease, and type 1 diabetes.
Cancer cell line-derived exosomes is a powerful tool in the study of cancer research. Cancer cells release higher levels of exosomes compared to normal cells. These exosomes play a crucial role in cancer development and progression by facilitating the communication between cancer cells, other cells including immune cells and stromal cells, and their microenvironment. More specifically, exosomes released from cancer cells can promote cell proliferation, angiogenesis and invasion to contribute to tumor progression. Furthermore, they can facilitate metastasis by promoting the formation of metastatic niches, facilitating tumor cell escape from the primary tumor, and promoting the survival and growth of cancer cells in distant organs. In addition, they also contribute to drug resistance by delivering molecules that alter the drug-sensitive status of recipient cells. Last but not least, exosomes derived from tumor cells are able to modulate the immune system, suppress anti-tumor immunity and enable tumor cells to escape immune surveillance.
Meanwhile, clinical research indicated that cancer cells derived exosomes are potential biomarkers for cancer diagnosis and prognosis, and potential therapeutic targets with strategies aimed at inhibiting exosome release or delivery of specific exosomal molecules. Nowadays, exosomes are also engineered to deliver therapeutic drugs to enhance the effectiveness of cancer treatments.
AcceGen provides high-quality Cancer Cell Line-Derived Exosomes, enable researchers to investigate the complex communication within the tumor microenvironment, support studies on the molecular mechanisms of cancer development and progression, drug resistance, immune evasion and cancer diagnosis, and explore exosome-based therapeutic strategies for cancer treatment.
Primary cell-derived exosomes are secreted by a wide range of primary cell types and act as intercellular messengers. These exosomes carry vital information and macromolecules, enable cellular communication and influence biological processes. Therefore, they are essential for studying natural cell-to-cell communication, exosome biological roles in various physiological and pathological processes including immune responses, tissue regeneration, and disease progression. In addition, exosomes can alter the biological response of recipient cells by delivering various cargo, potentially leading to disease-promoting or disease-restraining effects, exosomes derived from primary cells are particularly suited for therapeutic potential exploration in areas like cancer treatment, regenerative medicine, and gene therapy.
AcceGen provides high-quality Human Primary Cell-Derived Exosomes secreted by various primary cell types including fibroblasts, epithelial cells, endothelial cells, and muscle cells etc. These exosomes offer a physiologically relevant model and enable studies on the interactions between different cell types, contributing to unravel the complex roles of exosomes in various biological processes, disease pathogenesis and their potential for novel therapeutic interventions.
Biofluid-derived exosomes are released by cells in bodily fluids such as blood, urine, and CSF. They are enriched with proteins, lipids, and nucleic acids, and their contents reflect the health and status of their parent cells. As exosomes act as carriers for cell-to-cell communication, transferring information and cargo between cells, they have garnered significant attention as potential biomarkers for various diseases and as therapeutic agents. Particularly, exosomes derived from human biofluids are increasingly recognized and being explored as biomarkers for disease detection and monitoring, as well as therapeutic agents for drug delivery and regenerative medicine.
AcceGen provides high-quality Human Biofluid-Derived Exosomes, generated from different kinds of biofluid including plasma, serum, urine, saliva, CSF, breast milk, and ascites, each offering unique opportunities for research and clinical applications. For example, circulating exosomes in blood carry information about various tissues and organs, making them valuable for detecting diseases. Exosomes derived from urine can reflect kidney health and function, and are being investigated as biomarkers for kidney diseases such as CKD. Exosomes in CSF can provide insights into CNS diseases and are being studied for their role in neurodegenerative disorders.
These exosomes allow researchers to explore the molecular cargo in biofluids, advancing our ability to detect and monitor diseases in a non-invasive manner and opening new avenues for diagnostic and therapeutic applications.
In essence, biofluid-derived exosomes are a fascinating area of research with the potential to revolutionize healthcare, offering insights into disease mechanisms, biomarkers for early diagnosis, and new therapeutic strategies, offering a platform for personalized medicine.
